Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report report published on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target for the company. in a report on Tuesday, June 25th. Alliance Global Partners reaffirmed a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Stock Performance

Shares of NASDAQ ALIM opened at $5.54 on Friday. The business’s 50-day simple moving average is $5.56 and its 200-day simple moving average is $4.36. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.62 and a current ratio of 2.79. Alimera Sciences has a 52 week low of $2.61 and a 52 week high of $5.65. The firm has a market cap of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. As a group, equities research analysts expect that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Alimera Sciences by 61.1% during the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Glazer Capital LLC acquired a new stake in Alimera Sciences during the second quarter worth $3,067,000. Ancora Advisors LLC bought a new stake in Alimera Sciences in the 1st quarter valued at $915,000. Renaissance Technologies LLC raised its stake in shares of Alimera Sciences by 3.9% in the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after buying an additional 6,900 shares in the last quarter. Finally, Deltec Asset Management LLC bought a new position in shares of Alimera Sciences during the 2nd quarter worth about $690,000. 99.83% of the stock is owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).